Tarlatamab is a bispecific T cell engager targeting Delta-like ligand 3 (DLL3) and CD3. It previously passed the phase II trial for using in non-small cell lung cancer patients treatment.
Latest results of a phase 3 trial were published in The New England Journal of Medicine in 2025. In the prespecified interim analysis, the results show that patients treated with Tarlatamab, compared to those treated with chemotherapy (Topotecan, Lurbinectedin, Amrubicin) during or after first-line platinum-based chemotherapy, demonstrated:
- Longer overall survival (median: 13.6 months [95% CI, 11.1 to do not reached] vs. 8.3 months [95% CI, 7.0 to 10.2])
- A stratified hazard ratio of death: 0.6 (95% CI, 0.47 to 0.77; P < 0.001)
- Lower incidence of grade 3 or higher adverse events (54% vs 80%) and lower treatment discontinuation rates (5% vs. 12%)
Reference
- Mountzios, G., Sun, L., Cho, B. C., Demirci, U., Baka, S., Gümüş, M., ... & Rudin, C. M. (2025). Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy. New England Journal of Medicine.
- Ahn, M. J., Cho, B. C., Felip, E., Korantzis, I., Ohashi, K., Majem, M., ... & Paz-Ares, L. (2023). Tarlatamab for patients with previously treated small-cell lung cancer. New England Journal of Medicine, 389(22), 2063-2075
